Microba (ASX:MAP) core testing revenue jumps 92% as the break-even math finally clicks

A A$7m cost-out and a 25,000-test annual run rate reset how FY27 should be modelled

Microba Life Sciences (ASX:MAP) has delivered the sort of quarterly that quietly changes how a small-cap gets modelled. Core testing revenue grew 92% for FY26 and volume climbed 78% to 22,418 tests, with the exit run-rate now sitting above 25,000 tests annualised.

The headline growth is the easy part to celebrate. The more important number sits in the cash flow statement. Net cash used in operating activities fell 38% versus Q4 FY25 to A$3.43 million, and management has now substantially progressed a A$7 million per annum cost-out programme with the full benefit landing in H1 FY27.

Put those two lines together and the path to cashflow break-even that management promised back in June looks less like a hope and more like a schedule. Group revenue was actually down 6% for the year, but that reflects the deliberate phase-out of legacy products. Continuing product revenue grew 53% to A$12.73 million.

The remaining questions are about GI Navigator, the therapeutics partnering process, and whether the enterprise clinic channel keeps compounding at its current rate.

The enterprise clinic channel is doing the heavy lifting

Since Microba began targeting enterprise-style clinic contracts in November 2025, it has signed 43 key accounts that sold 5,606 tests in Q4 alone, up 87% quarter-on-quarter. Management says those accounts represent ordering potential of over 24,000 tests per year as they mature.

The pipeline is deeper still. There are more than 175 key account targets sitting behind the signed base, with a modelled ordering potential above 80,000 tests per annum. Even if only a fraction convert on the current cadence, the growth engine has visible fuel through FY27.

The UK is the sleeper. Microbiome Explorer sold 825 tests in the UK in Q4, up 92% on the prior corresponding period, with ordering clinicians up 85%. The commercial motion clearly travels, which matters for the therapeutics story too.

The A$7m cost-out is the number to circle

The streamlining programme targets roughly A$7 million of annualised cash cost reduction, concentrated in functions where the product build phase is complete and in back-office areas benefiting from AI automation. Management stresses it does not touch front-line sales or the growth engine.

The Q4 numbers already show this working. Staff cash costs are down about A$0.9 million versus the prior corresponding period, admin and corporate costs down A$0.7 million, and manufacturing and operating costs down another A$0.7 million. That is not a plan on a slide. It is landing in the cash flow.

We think this is the single most important line in the announcement. Small-cap healthcare has a patchy history of promising structural cost savings that quietly disappear. Microba is showing the cash number moving before the AI narrative gets tested at full scale.

Therapeutics is now a real option, not a distraction

MAP-315, the ulcerative colitis lead asset, had its Phase 1 trial provisionally accepted for publication in Nature Communications during the quarter. That is a credibility marker that opens doors in a way BIO partnering meetings on their own do not.

The sector backdrop has also shifted. Six live biotherapeutic clinical readouts between November 2025 and July 2026, including Maat Pharma’s positive Phase 3 GvHD result, have de-risked the modality that prospective partners were waiting on. The formal partnering campaign that kicked off this month walks into a warmer room than the one Microba faced 12 months ago.

Internal R&D spend on therapeutics remains paused. That is the correct posture. Any therapeutics outcome from here is optionality that the market currently ascribes very little value to.

The Investors Takeaway for Microba Life Sciences

The GI Navigator launch in September 2026 is the next stress test. Thirty-five early-access sales are already in, and management is positioning the product to open up the medical doctor segment beyond the integrative and gastroenterology clinicians the current portfolio serves.

Cash on hand of A$7.95 million at 30 June, plus the second tranche of the placement settling on 28 July and a A$2.0 million R&D loan facility, gives Microba enough runway to see the cost-out through and prove the break-even math. If the enterprise clinic base keeps compounding and GI Navigator lands, the FY27 story is a very different one from the FY26 story. Investors can read our previous coverage of this name at stocksdownunder.

The skeptical read is that the company still needs to convert pipeline into activated accounts and prove GI Navigator sells at scale. But the direction of travel across volume, cash burn and margin is now moving the same way at the same time, which has not been true for most of the past two years.